Isthmus Partners’s Impax Laboratories, Inc. IPXL Stock Holding History

Isthmus Partners’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-19,193	Closed	-$608K	–	280
2014 Q4	$608K	Buy	+19,193	New	+$562K	0.21%	69

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Isthmus Partners's IPXL Position: Q1 2015 in Review

Isthmus Partners sold out of Impax Laboratories, Inc. (IPXL) in Q1 2015, closing a stake of 19,193 shares — an estimated $608K sold.

Isthmus Partners first reported a position in IPXL in Q4 2014 and held it in 1 quarter. The position peaked at $608K in Q4 2014. 197 funds tracked by Wall St. Rank hold IPXL as of Q1 2015.

Isthmus Partners reported no remaining Impax Laboratories, Inc. position as of Q1 2015 after selling out during the quarter.
Isthmus Partners sold 19,193 Impax Laboratories, Inc. shares in Q1 2015, an estimated $608K.
Isthmus Partners first reported a position in Impax Laboratories, Inc. in Q4 2014 and held it in 1 quarter.
Isthmus Partners's Impax Laboratories, Inc. position peaked at $608K in Q4 2014.
197 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2015.

Based on Isthmus Partners's 13F filing for Q1 2015, filed 1 Jun 2015.